FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 25 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR ¿Pueden confundirse los síntomas del cáncer con la menopausia? November 1, 2022 FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma October 6, 2022 Wawa Employee Saves Life Of Customer Who Stopped Breathing After A... January 20, 2022 Taking Control – Risks vs. Benefits July 14, 2020 Load more HOT NEWS The Horror Story Of What Can Happen When You Don’t Pay... New on NCI’s Websites for March 2022 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in...
